Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
EGL Genetic Diagnostics, |
RCV000335617 | SCV000110808 | pathogenic | not provided | 2015-08-06 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000335617 | SCV000329083 | pathogenic | not provided | 2018-08-29 | criteria provided, single submitter | clinical testing | The c.465+1G>A variant is a common pathogenic variant in central and western European populations associated with metachromatic leukodystrophy (MLD) with no functional arylsulfatase A activity and designated as an I-type (Infantile/juvenile-onset) ARSA allele (Polten et al., 1991; Biffi et al., 2008; Gomez-Ospina, 2017). The c.465+1G>A variant destroys the canonical splice donor site in intron 2, and is expected to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. We interpret c.465+1G>A as a pathogenic variant. |
Center for Pediatric Genomic Medicine, |
RCV000335617 | SCV000610089 | pathogenic | not provided | 2017-04-24 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000020319 | SCV000627142 | pathogenic | Metachromatic leukodystrophy | 2018-12-19 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 2 of the ARSA gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is present in population databases (rs80338815, ExAC 0.1%). This variant has been reported in the literature in individuals affected with metachromatic leukodystrophy (PMID: 1670590, 18786133, 21167507, 26462614, 9090526, 11456299, 9600244, 7825603). This variant is also known in the literature as c.459+1G>A, IVS2+1G>A, and allele I or 0. ClinVar contains an entry for this variant (Variation ID: 3051). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ARSA are known to be pathogenic (PMID: 8962139, 10477432). For these reasons, this variant has been classified as Pathogenic. |
Counsyl | RCV000020319 | SCV000677978 | pathogenic | Metachromatic leukodystrophy | 2015-06-14 | criteria provided, single submitter | clinical testing | |
Integrated Genetics/Laboratory Corporation of America | RCV000020319 | SCV000696808 | pathogenic | Metachromatic leukodystrophy | 2017-05-21 | criteria provided, single submitter | clinical testing | Variant summary: The ARSA c.465+1G>A variant involves the alteration of a conserved intronic nucleotide and 5/5 splice prediction tools predict a significant impact on normal splicing, which has been functionally supported (Zlotogora_1994 and Polten_1991). This variant was found in 88/111568 control chromosomes at a frequency of 0.0007888, which does not exceed the estimated maximal expected allele frequency of a pathogenic ARSA variant (0.0027951). Multiple publications have cited the variant in homozygous and compound heterozygous affected individuals diagnosed with late-, juvenile- and adult-onset depending on the second mutation in trans. The variant of interest has been indicated to be a common founder mutation (Zlotogora_1994 and Polten_1991). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. |
Fulgent Genetics, |
RCV000020319 | SCV000893600 | pathogenic | Metachromatic leukodystrophy | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Illumina Clinical Services Laboratory, |
RCV000020319 | SCV000915006 | pathogenic | Metachromatic leukodystrophy | 2018-12-18 | criteria provided, single submitter | clinical testing | The ARSA c.465+1G>A variant, also referred to as c.459+1G>A, has been described as one of the most common pathogenic variants for arylsulfatase A deficiency occurring in the central and western European populations (Fluharty et al. 2006). Across a selection of the available literature, the c.465+1G>A variant has been identified in at least eight homozygotes, 16 compound heterozygotes, and 25 heterozygotes with an uncharacterized second allele, giving an allele frequency ranging from 7.5% to 37% in patients with arylsulfatase A deficiency (Polten et al. 1991; Eto et al. 1993; Draghia et al. 1997; Berger et al. 1997; Lugowska et al. 2005; Biffi et al. 2008; Shukla et al. 2011). Biochemical analyses indicate that the variant is associated with no residual arylsulfatase A activity (Polten et al. 1991). The c.465+1G>A variant is reported at a frequency of 0.00132 in the European (non-Finnish) population of the Exome Aggregation Consortium. Based on the collective evidence, the c.465+1G>A variant is classified as pathogenic for arylsufatase A deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
OMIM | RCV000003192 | SCV000023350 | pathogenic | Metachromatic leukodystrophy, juvenile type | 2001-07-01 | no assertion criteria provided | literature only | |
OMIM | RCV000003194 | SCV000023352 | pathogenic | Metachromatic leukodystrophy, adult type | 2001-07-01 | no assertion criteria provided | literature only | |
Gene |
RCV000020319 | SCV000040694 | pathologic | Metachromatic leukodystrophy | 2011-08-25 | no assertion criteria provided | curation | Converted during submission to Pathogenic. |
Mayo Clinic Genetic Testing Laboratories, |
RCV000335617 | SCV000801471 | pathogenic | not provided | 2018-02-07 | no assertion criteria provided | clinical testing |